Table 1 Pre-treatment patient characteristics and baseline parameters
Variable | Total cohort | Patients with ≥1 persisting mutation in remission | Patients without persisting mutation in remission | p |
|---|---|---|---|---|
Patient number | n = 126 | n = 50 | n = 76 | |
Age [years], median (range) | 54 (20–80) | 63.5 (21–78) | 48 (20–80) | <0.0001 |
Pts. ≤60 years/>60 years | 84/42 | 21/29 | 63/13 | |
Male gender | 62 (49%) | 21 (42%) | 41 (54%) | 0.21 |
Disease type | ||||
De novo AML | 108 (86%) | 40 (80%) | 68 (89%) | 0.079 |
Secondary AML | 9 (7%) | 3 (6%) | 6 (8%) | |
Therapy-related AML | 6 (5%) | 5 (10%) | 1 (1%) | |
ECOG performance status | 0.44 | |||
0 | 45 (36%) | 15 (30%) | 30 (39%) | |
1 | 50 (40%) | 20 (40%) | 30 (39%) | |
2 | 7 (6%) | 4 (8%) | 3 (4%) | |
≥3 | 6 (5%) | 2 (4%) | 4 (5%) | |
WBC [ × 109/l], median (range) | 20.3 (0.5–406) | 26.8 (0.5–406) | 15.2 (0.9–364) | 0.41 |
Blast count at diagnosis | ||||
% Bone marrow blasts, median (range) | 72 (17–97) | 73.5 (17–97) | 71 (17–97) | 0.68 |
% Peripheral blood blasts, median (range) | 37 (0–96) | 42 (0–96) | 31 (0–96) | 0.73 |
MRC cytogenetic risk category | 0.029 | |||
Favorable | 8 (6%) | 0 (0%) | 8 (11%) | |
Intermediate | 102 (81%) | 42 (84%) | 60 (79%) | |
Adverse | 11 (9%) | 6 (12%) | 5 (7%) | |
Missing | 5 (4%) | 2 (4%) | 3 (4%) | |
ELN 2017 classification | 0.92 | |||
Favorable | 49 (39%) | 19 (38%) | 30 (39%) | |
Intermediate | 37 (29%) | 14 (28%) | 23 (39%) | |
Adverse | 40 (32%) | 17 (34%) | 23 (30%) | |
Patients with gene mutations detected in pretreatment sample | ||||
NPM1 | 57 (45%) | 26 (52%) | 31 (41%) | 0.20 |
DNMT3A | 43 (34%) | 28 (56%) | 15 (20%) | <0.0001 |
FLT3-ITD | 40 (32%) | 15 (30%) | 25 (33%) | 0.85 |
TET2 | 18 (14%) | 12 (24%) | 6 (8%) | 0.018 |
RUNX1 | 15 (12%) | 9 (18%) | 6 (8%) | 0.10 |
ASXL1 | 13 (10%) | 9 (18%) | 4 (5%) | 0.034 |
SRSF2 | 11 (9%) | 8 (16%) | 3 (4%) | 0.025 |
CEBPA | ||||
-Mono-allelic | 3 (2%) | 3 (6%) | 0 (0%) | 0.060 |
-Bi-allelic | 6 (5%) | 1 (2%) | 5 (7%) | 0.40 |
Remission status post induction | 0.12 | |||
CR | 98 (78%) | 35 (70%) | 63 (83%) | |
CRi | 28 (22%) | 15 (30%) | 13 (17%) | |
Allogeneic transplantation | 80 (64%) | 30 (60%) | 50 (66%) | 0.57 |
In first CR/CRi | 53 | 19 | 34 | |
After relapse | 27 | 11 | 16 | |
Material studied (diagnosis/remission/relapse) | – | |||
Bone marrow | 115/117/35 | 70/72/17 | 45/45/18 | |
Peripheral blood | 11/9/1 | 6/4/0 | 5/5/1 | |
